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Background: Many patients with atrial fibrillation (AF) at high risk for
thromboembolic events are not candidates for long-term oral anticoagulation (OAC).
The left atrial appendage (LAA) is the major site of thrombus formation in non-valvular
AF. We report our initial results for LAA occlusion with the AMPLATZER® Cardiac
Plug (ACP) (St. Jude Medical, Plymouth, MN).
Methods: A multicenter European Post Market Registry was initiated to evaluate the
performance of the ACP device in closure of the LAA. A total of 145 pts with non-
valvular AF underwent ACP implantation contributing to the data of this interim
analysis.
Results: The majority of patients (60%) had a history of permanent AF. Mean age was
73.6 ± 8.9, mean CHADS2 score 2.6 ± 1.3. Prior stroke or TIA was reported by 38%
of patients. The majority underwent the procedure for intolerance of Warfarin; only
3.3% of patients were on active OAC prior to implant. The ACP device was
successfully implanted in 96.5% of patients with no device embolizations during the
implant procedure. Acute device/procedure related Adverse Events (AEs) occurred
within 7 days post procedure in 8 out of 145 patients (5,5%), consisting of 3 serious
pericardial effusions, 3 device embolizations, 1 cardiac perforation, and 1 arteriovenous
fistula. All device embolizations occurred early in the learning curve for each of the
implanters. During follow-up after 7 days post implant we observed 3 cases of
thrombus on the device and 1 case of late device embolization. Root cause analysis of
thrombus formation demonstrated the importance of proper implant technique and
adequate anti-thrombotic regimen.
Conclusion: The ACP device demonstrated excellent implant success and closure rates.
The rate of AEs compares favorably with other devices despite the high risk patients
enrolled in the Registry. The enrollment goal of 200 patients is expected to be achieved
in the fall of 2011 with final results available in 2012.
TCT-113
Safety and Efficacy of Balloon Atrial Septostomy for Advanced Pulmonary
Hypertension in Patients Failing Prostanoid Therapy
Brooks T Kuhn, Javed Usman, Thomas W Smith, William J Bommer, Charles K
Whitcomb, Roblee P Allen, Jason Rogers
UC Davis Medical Center, Sacramento, CA
Background: Prostanoid therapy improves quality of life and may increase survival
in patients with advanced pulmonary hypertension (PH). Balloon atrial septostomy
(BAS) can palliate or a serve as a bridge to transplantation for patients resistant to
medical therapy. The safety and efficacy of BAS in the era of prostanoid therapy has
not previously been reported.
Methods: All patients had progressive symptoms despite prostanoid therapy at the
time of their first BAS. Eleven patients who underwent a total of 16 septostomies
between 2004-11 were included in this retrospective analysis.
Results: Patients were aged 46.9 years ± 10.5 with 8/11 women. Etiologies included
idiopathic (6), methamphetamine (3), scleroderma (1), and anorexigen (1). Survival at
a mean of 739 days was 73%. No patient died within 24 hours post-procedure. 30-day
and 1-year survival were both 82%. Four4 subjects required repeat BAS due to shunt
closure; 3 subjects were successfully bridged to transplant. 9 of 11 patients had
improvement by one functional class. Hemodynamic and echocardiographic
measurements are presented in Table 2in the table. All non-survivors were male and
had higher baseline serum creatinine, mean right atrial pressure, right ventricular (RV)
end diastolic pressure and left ventricular filling pressures, and lower RV ejection
fraction. Mortality was associated with unchanged post-septostomy cardiac output
despite an increase in LVEDP. Tricuspid annular plane systolic excursion (TAPSE)
and serum BNP were not different between the two groups.
Conclusion: BAS appears to be a promising therapy for select PH patients who have
symptomatic progression despite prostanoid therapy. Survival is comparable to prior
reports of patients undergoing BAS in the pre-prostanoid era.
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Background: Balloon aortic valvuloplasty (BAV) for calcific aortic stenosis has
undergone a renaissance, due to transcatheter aortic valve implantation (TAVI) and its
integral use of BAV. We sought to characterise UK BAV experience in the TAVI era.
Methods: Data from 423 patients who had undergone BAV from March 2003 to April
2010 at 14 centres across the United Kingdom were analysed.
Results: Patients were aged 80.9±8.5 (mean±SD) years; 55.0% were male and the
mean logistic EuroScore was 27.8±16.8%. BAV was performed for palliation (40.8%)
or as a bridge to either TAVI (34.1%) or surgical aortic valve replacement (sAVR)
(12.8%). Procedural success was 98.5%, with a median balloon size of 20mm and
2.4±1.6 inflations used. The peak transaortic gradient fell from 77.8±28.2 to 53.5±19.9
mmHg (p<0.001). Procedural complications were: death (2.4%), blood transfusion of
≥2 units (1.2%), cardiac tamponade (1.0%), stroke (1.0%), vascular surgical repair
(1.0%), coronary embolisation (0.5%), worsening of AR by 2 grades (0.5%) and
permanent pacing (0.2%). Mortality at 30-days was 13.2% and 34.8% at 12 months.
At a mean follow-up of 269.7±275.6 days the adverse events seen were death (39.3%),
TAVI (18.2%), sAVR (7.0%) and repeat BAV (3.2%). Multivariate Cox proportional
hazard analysis demonstrated that survival was adversely effected by an urgent (Hazard
Ratio 1.7; 95% Confidence Interval 1.2-2.4) or emergent presentation (HR 3.7; 95%CI
2.3-6.1), poor left ventricular systolic function (HR 1.5; 95%CI 1.1-2.2) and the
presence of coronary disease (HR 1.5; 95%CI 1.1-2.2). The presence of moderate or
severe calcification was inversely related to time to death (HR 0.4; 95%CI 0.3-0.7).
Kaplan Meier analysis demonstrated that repeat BAV had no statistically significant
effect upon survival compared to no treatment(logrank=0.08) but subsequent TAVI or
sAVR improved survival (logrank<0.001).
Conclusion: BAV offers good immediate efficacy at an acceptable risk of
complications. Medium term freedom from death is poor in the absence of definitive
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therapy, however BAV provides effective bridging to definitive therapy.
TCT-115
Inmediate and Long-Term Results of Mitral Balloon Valvuloplasty in Patients
With Severe Pulmonary Hypertension
Rodrigo Blanco, Ricardo Sarmiento, Federico Blanco, Gerardo Gigena, Andrea
Rodriguez, Alejandro Garcia Escudero, Juan Gagliardi, Jorge Lax, Jorge Szarfer,
Miguel Riccitelli
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Background: OBJETIVE: assess the long-term outcome of percutaneus mitral balloon
valvuloplasty (PMV) in patients (pts) with severe pulmonary hypertension(PHT).
Methods: PMV was performed in 132 consecutive pts. 39 (29,5%) had severe PHT
defined as resting pulmonary artery systolic pressure (PAPs) > 60 mmHg at baseline
(group A), and 93 controls pts(70,5%) (group B). Pts were clinical and
echocardiographicaly evaluated immediately after procedure 6 months after and once
per year thereafter, evaluating echocardiographic Wilkins score (ES), mitral valve area
(MVA),PAPs and mitral regurgitation(MR). Following endpoints were considered:
restenosis(RS),mitral valve replacement (MVR) or MBV requirement, or
cardiovascular death. A logistic regression model was adjusted to determine
independent predictors for outcome. A value of p <0.05 was considered significant.
Results: Median follow-up was 48 months (Q25-75: 24-84). Group A pts aged 42,3±
14 years; 89,7% (31 pts) were female; 23% pts had atrial fibrillation (AF)and 37
pts(94,8 %) had dispnea (18 p NYHA II and 19 p NYHA III). Median ES was 7(Q25-
75: 5-9).No differences on baseline characteristics, success achievement, RS and follow
up symptoms between Groups were found. MVA increased from 0,90 cm2 (Q25-
75:0.82-1.02) to 1,75 cm2 (Q25-75: 1,50-2,02). PAPs fell from 57,5 mmhg
(Q25-75:51-65) to 35 mmHg (Q25-75: 30-50) in Group A and from 38 mmhg (Q25-
75:30-43) to 30 mmHg (Q25-75: 27-35) in Group B. Success was associated with ES
< 8 (p=0.01) both in group A and B. Long term outcomes are shown in table 1.There
were 3 in hospital deaths and 3 deaths during follow-up. 10 pts required new PMV; 6
p RVM. RS at 60 months follow-up was associated with ES > 8 in both groups, A (p=
0,03) B (p= 0,02).
Table 1.
Mitral valve area and pulmonary artery systolic pressure at long-term follow up in
Group A (pts with PHT) and Group B(control)
Conclusion: PMV is a safe and effective technique for treating patients with mitral
stenosis and severe PHT. Despite a gradual MVA decrease, most patients remain
asymptomatic and PAPS values were stable in the long term follow up.
TCT-116
Long-Term Follow-up After Myocardial Contrast Echocardiography-Guided
Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy
Amir-Ali Fassa, Thierry Lefevre, Marie-Claude Morice, Jean-François Piéchaud,
Marie-Christine Malergue, Yves Louvard, Philippe Garot, Bertrand Cormier
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Background: Our aim is to report the immediate and long-term results of alcohol
septal ablation (ASA) guided by myocardial contrast echocardiography (MCE) for
treatment of symptomatic hypertrophic obstructive cardiomyopathy from a high-
volume centre.
Methods: We reviewed the data of 161 patients (88 males) who underwent MCE
guided ASA at our institution from 2000 to 2011.
Results: Mean age was 56.4±15.9 years (range 8-87). Medical treatment included beta-
blockers (75%), calcium-channel antagonists (49%) and disopyramide (2%). 22% had
prior pacemaker (PM) implantation, 3% prior implantable cardioverter-defibrillator
(ICD) and 4% prior cardiac surgery. At baseline, mean New York Heart Association
(NYHA) functional class was 2.8±0.6. Mean left ventricular outflow tract (LVOT)
peak gradient and septal thickness were 92±45mmHg and 23.0±3.8 mm, respectively.
During ASA, 2.0±0.8ml of absolute alcohol was injected in 1.2±0.4 septal perforators.
Final procedural LVOT peak gradient was 20±22mmHg. Procedural success
(immediate LVOT peak gradient reduction >50%) was achieved in 94%. Complications
included coronary dissection requiring stent implantation (1 procedure). There were 2
in-hospital deaths (1 refractory ventricular arrhythmia, 1 complete atrioventricular
block). In-hospital permanent PM implantation was required following 8.7% of
procedures. One patient required an ICD for non-sustained ventricular tachycardia.
Mean peak CK was 932±491 IU/L. At a mean follow-up of 2.3±1.8 years after the
procedure (range 0-8.4), there were 7 additional deaths (overall annual mortality of
2%). Repeat ASA was required in 12 patients (7%) and a new ICD was needed in 1
patient (5%). Mean NYHA class was improved to 1.2±0.5.
Conclusion: MCE-guided ASA is associated with a high rate of immediate success
and a low rate of procedural complications. In addition, long-term follow-up shows
sustained clinical benefit with a low rate of adverse events (annual mortality lower
than the expected rate of 3-4% in this high-risk population).
TCT-117
Off-pump, Trans-apical Placement of Artificial Chordae Tendinae to Correct
Mitral Insufficiency: European Trial Update
Richard Daly1, Giovanni Speziali2, John Seaberg4, John Zentgraf4, Joerg Seeburger3
1Mayo Clinic, Rochester, MN; 2University of Pittsburgh Medical Center, Pittsburgh,
PA; 3Heart Center Leipzig, Leipzig, Germany; 4Neochord, Inc., Minneapolis, MN
Background: The prognostic value of correction of severe mitral regurgitation (MR)
due to leaflet prolapse is well established. Artificial chordae tendinae (ACT) using
polytetrafluoroethylene sutures have been shown to provide durable support to
prolapsing leaflets in open surgical procedures.
Methods: A novel instrument (Neochord, Inc., Minneapolis, MN) allows off-pump,
trans-apical placement of ACT to a prolapsed segment of a mitral leaflet using
echocardiographic guidance. The ACT is anchored at the left ventricular apex with the
proper length established on the beating heart with echo guidance. The TACT Trial
(Transapical Placement of Artificial Chordae Tendinae) is a non-randomized,
prospective evaluation of the Neochord instrument. We report the first patients enrolled
in this trial, which is ongoing in Europe.
Results: Thirteen patients have been enrolled to date in the TACT Trial. ACT were
not placed in 2 patients for patient-specific reasons. ACT were deployed in 11 patients
with immediate procedure reduction of MR in 8/11 patients to < 1+, and in 2/11 MR
was 2+ (91% with MR < 2+). Single ACT were placed in the prolapsed mitral leaflet
in the first 2 patients and both developed recurrent MR within 30 days treated with
standard open mitral valve repair (SOR). Multiple ACT were deployed in the next 9
patients. Results at 30 days for patients with multiple ACT are: 3 patients MR < 1+, 2
patients MR = 2+ and 4 patients MR > 2+ (2 patients underwent SOR). To date, 3
patients have completed 12 months and 2 patients have completed 6 months follow-
up; all 5 patients demonstrate stable results (no change in MR from 30 days).
Conclusion: In conclusion, the very early results of off-pump, trans-apical placement
of ACT with the Neochord instrument show early, acute surgical success (MR < 1+)
in 73% of patients (91% had MR < 2+), but recurrent MR developed in several patients.
Use of multiple ACT to distribute tension on the leaflet has probably been helpful.
Refinements in patient selection are expected to contribute to improved results as
experience continues.
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Background: Patients with severe aortic stenosis and reduced left ventricular ejection
fraction (LVEF) have a poor prognosis with conservative therapy but a high operative
mortality when treated surgically. The objective of this study was to evaluate the impact
of severe LVEF impairment on clinical and echocardiographic outcomes following
transcatheter aortic valve implantation (TAVI)
Methods: From June 2007 to December 2010 a total of 982 consecutive patients
undergoing TAVI with third-generation 18F CoreValve device were included in the
Italian Registry. One hundred and forty patients (14%) had a severe LVEF impairment
(LVEF ≤35%; group A) while 842 (86%) had LVEF >35% (group B). Mean follow-
up time was 16±10 months (interquartile range 8-25 months).
Results: At baseline, group A patients had a significantly higher clinical risk profile
than group B (Logistic Euroscore 33.9±18.7 vs 21.3±12.1, p<0.0001; NYHA class III-
IV 85% vs 70%, p=0.0003; previous myocardial infarction 25.7% vs 17.7%, p=0.02),
although they were less elderly (80±7 vs 82±6 years, p<0.0001). Procedural mortality
was higher in group A (4.3% vs 1.3%, p=0.02), although procedural success was not
significantly lower (94.3% vs 96.8%, p=0.14). At 30 days, overall mortality was 10.7%
in group A vs 4.4% in group B (p=0.002), while cardiovascular mortality was 10.7%
vs 3.9%, respectively (p=0.0006). At 1 year, actuarial survival was 80.2±3.4% vs
85.2±1.3%, respectively (p=0.02), while at 2-year follow-up it was 77.8±3.7% vs
83.1±1.4% (p=0.02). Group A patients showed marked LV reverse remodelling at 1
year, with a significant improvement of LVEF (LVEF increase of 14±13% vs 2±10%,
p<0.0001) compared with group B.
Conclusion: Patients affected by critical aortic stenosis and severe LVEF impairment
had higher procedural and 30-day mortality after TAVI compared with normal or
moderate LVEF. However, this subset of patients showed the best clinical and
echocardiographic outcomes at 1 year follow up.
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